XOMA (US:XOMA) — Company Overview, News & Financial Data
XOMA focuses on developing innovative antibody-based therapeutics, partnering to advance drug research and development.
XOMA
XOMA (NASDAQ:XOMA) is a biotech entity focused on the discovery and development of innovative antibody-based therapeutics. The company’s operations revolve around licensing its extensive portfolio of patents and clinical development products to other biotechnology and pharmaceutical companies. XOMA's projects often involve developing partnerships and collaborations to advance the research and development of drugs with the potential to address a wide range of diseases and conditions. The primary objective of XOMA is to leverage its proprietary technology and scientific expertise to create a robust pipeline of therapeutic candidates, which provides the foundation for future growth and innovation in the medical field.
Snapshot
Operations
Products and/or services of XOMA
- Royalty Agreements Management, generating revenue through a portfolio of partnered assets and milestone payments.
- License XOMA 358, an insulin receptor modulator for hyperinsulinism disorders.
- License Gevokizumab, targeting IL-1 beta for inflammatory conditions.
- Out-licensing Technologies, providing proprietary technologies to partners for drug development.
- Phage Display Libraries for antibody discovery and development, offering partners tools for novel therapeutics.
- Partnered Discovery Projects, collaborating on the identification and development of early-stage drug candidates.
XOMA executive team
- Mr. Owen P. Hughes Jr.CEO & Director
- Mr. Bradley SitkoChief Investment Officer
- Mr. Jeffrey TrigilioChief Financial Officer
- Ms. Maricel Perea MontanoChief Legal Officer